Plasmodium Vivax Malaria
14
3
3
7
Key Insights
Highlights
Success Rate
78% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
14.3%
2 terminated out of 14 trials
77.8%
-8.7% vs benchmark
43%
6 trials in Phase 3/4
0%
0 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (14)
Targeting High Risk Populations With Enhanced Reactive Case Detection in Southern Lao Peoples Democratic Republic
Targeting High Risk Populations With Enhanced Reactive Focal Mass Drug Administration in Thailand
Phase IIa/b Trial of PvCS/Montanide ISA-51 Malaria Vaccine in Adults in Chocó, Colombia
Vivax Elimination With Tafenoquine (VET) Study
FocaL Mass Drug Administration for Vivax Malaria Elimination
ACT vs CQ With Tafenoquine for P. Vivax Mono-infection
Southeast Asia Dose Optimization of Tafenoquine
Papua New Guinean Duffy Negativity And Vivax Malar
Clinical Trial for the Development of a Safe Malaria Challenge Model That Can be Reproduced in Humans
Malaria in Early Life Study
PpPfs25/ISA51 and ScPvs25/ISA51 Vaccines for Malaria
Antimalarial Drug Susceptibility and Molecular Characterization of Plasmodium Vivax Isolates in Vietnam
DSM265 Phase IIa Investigation Treating Plasmodium Falciparum or Vivax
Efficacy of Artemisinin Combination Therapies for the Treatment of Uncomplicated P. Vivax in Pregnancy in Brazil (PAACT-PV)